Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn’s Disease Treated With Infliximab [Remicade®] or Conventional Therapy
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjw221
Abstract: Background and Aims The ENCORE registry aimed at comparing the long-term safety of Crohn's disease [CD] treatment with infliximab [Remicade®] and with conventional therapies in real-world clinical practice. Methods The 5-year, prospective, observational ENCORE registry… read more here.
Keywords: year; safety; conventional therapy; infliximab remicade ... See more keywords